1.. Introduction
================

Neurofibromatosis type 1 (NF1; OMIM 162200) is one of the most common hereditary disorders. It is predominantly characterized by multiple café-au-lait macules (CALM), skin-fold freckling, Lisch nodules and neurofibromas. However, as the condition exhibits age-dependent characteristics and there are a number of other overlapping syndromes and similar diseases, it is usually difficult to make an early clinical diagnosis. Currently, although there are numerous comprehensive detection methods available for molecular diagnosis of NF1, the highest sensitivity of any of these methods is \~95% ([@b1-mmr-14-05-4023],[@b2-mmr-14-05-4023]). In addition to the limitations of detection by these approaches, cases of mosaic NF1 have been reported and there may exist other known or undefined genetic conditions with similar phenotypes. KIT ligand (KITLG) and its receptor KIT proto-oncogene receptor tyrosine kinase (KIT) activate the Ras/mitogen-activated protein kinase (MAPK) signaling pathway and they are critical in the control of physiological and pathological cutaneous pigmentation, including CALM ([@b3-mmr-14-05-4023]). Known disorders with CALM comprise: i) A group of genetic syndromes resulting from germline mutations in genes that encode components or regulators of the Ras/MAPK signaling pathway, designated RASopathies, which consists of Noonan syndrome (NS; OMIM 163950), Legius syndrome \[formerly termed NF1-like syndrome (NFLS); OMIM 611431\], LEOPARD syndrome (LS; OMIM 151100), Costello syndrome (CS; OMIM 218040) and cardiofaciocutaneous syndrome (CFC; OMIM 115150), ii) disorders involving the KITLG/KIT signaling pathway, including piebaldism (OMIM 172800) and familial progressive hyperpigmentation (FPH; OMIM 145250). Although there are unique phenotypic characteristics for these conditions, certain syndromes remain highly overlapping and the differential diagnosis between them and NF1 is complex.

Our group recently conducted a large molecular research investigation into NF1 in a Chinese population ([@b4-mmr-14-05-4023]--[@b6-mmr-14-05-4023]). Patients without *NF1* mutations who exhibited CALM were observed, and in a further study, other syndromes were demonstrated, including an atypical LS patient with a *PTPN11* mutation, a piebaldism patient with a *KIT* mutation and a familial progressive hyper- and hypopigmentation (FPHH) patient with a *KITLG* mutation.

The present review discusses these KITLG/c-Kit- and Ras/MAPK signaling pathway-associated 'NF1-like' inherited diseases, and proposes a molecular screening strategy to aid the determination of a definitive diagnosis.

2.. The RASopathies with CALM
=============================

### NFLS

NFLS presents predominantly with CALM, intertriginous freckling and certain less common manifestations (\~20%), including neurocognitive impairment, developmental delay and macrocephaly, usually without neurofibromas, Lisch nodules, optic pathway glioma and other tumors ([@b7-mmr-14-05-4023],[@b8-mmr-14-05-4023]). More than 60% of the patients have a family history of the condition ([@b9-mmr-14-05-4023]). These features meet three of the National Institutes of Health (NIH) diagnostic criteria for NF1 ([@b10-mmr-14-05-4023]), thus, it is not reliable to distinguish NF1 from NFLS relying solely on clinical examination. Germline loss-of-function sprouty related, EVH1 domain containing 1 (*SPRED1*) mutations are responsible for this syndrome, which is most similar to NF1 in early childhood ([@b11-mmr-14-05-4023]). It is estimated that \~1--4% of individuals with multiple CALM harbor heterozygous *SPRED1* mutations ([@b7-mmr-14-05-4023],[@b9-mmr-14-05-4023]). In subjects with familial CALM, with or without freckling and no other NF1 features, 73% and 19% carry pathogenic *NF1* mutations or *SPRED1* mutations, respectively ([@b7-mmr-14-05-4023]), which further indicates that genetic testing is useful in diagnosis in these cases (92%). SPRED1 is involved in regulation of the MAPK signaling pathway, previous studies have demonstrated a loss of heterozygosity in pediatric acute myeloblastic leukemia, acting as a tumor suppressor ([@b12-mmr-14-05-4023],[@b13-mmr-14-05-4023]), this also indicates that this syndrome increases the risk of developing specific hematological malignancies, as well as other rare conditions, including kidney and lung cancer ([@b8-mmr-14-05-4023]).

### LS

LS is an autosomal dominant RASopathy, predominantly caused by mutations in protein tyrosine phosphatase, non-receptor type 11 (*PTPN11*; 85%), in addition to less common genes, Raf-1 proto-oncogene, serine/threonine kinase (RAF1) and B-raf proto-oncogene, serine/threonine kinase (*BRAF*) (10%). Individuals present with characteristic multiple lentigines, and relatively common features of RASopathies, including facial dysmorphia, myocardial and valvular abnormalities, and hearing loss. It is hard to clinically distinguish LS from other RASopathies, such as NF1 and NS, while molecular diagnosis is relatively reliable.

Twelve different missense *PTPN11* mutations (Tyr279Cys/Ser, Ala461Thr/Ser, Gly464Ala, Thr468Met/Pro, Arg498Leu/Trp, Gln506Pro and Gln510Glu/Pro) ([@b14-mmr-14-05-4023]--[@b18-mmr-14-05-4023]) were reported to result in LS. Two of these mutations (Tyr279Cys and Thr468Met) account for \~65% of the cases. Notably, these mutations cluster in the catalytic protein tyrosine phosphatase domain (amino acid residues, 221--524) ([@b19-mmr-14-05-4023]), as in the allelic disorder, NS, the majority of missense mutations, small deletions and indels ([@b20-mmr-14-05-4023],[@b21-mmr-14-05-4023]) are associated with the N-SH2 domain (amino acid residues, 3--104) ([@b14-mmr-14-05-4023]). Contrary to the gain-of-function changes resulting in excessive PTPN11 activity in NS ([@b12-mmr-14-05-4023]), LS mutants are catalytically defective and exert a dominant negative effect ([@b22-mmr-14-05-4023]), suggesting that mutation type and region are important in the underlying pathogenic mechanisms and differential diagnoses of NS and LS. A recent study has suggested that LS-associated mutations may increase melanin synthesis in melanocytes via the activation of Akt/mammalian target of rapamycin signaling, thus, resulting in a phenotype with multiple lentigines ([@b23-mmr-14-05-4023]).

Furthermore, a recent study identified a novel heterozygous MAPK kinase 1 (*MAP2K1*) mutation in LS, Glu102Gly ([@b24-mmr-14-05-4023]), this is notable as mutations in this gene are usually associated with CFC. LS shares numerous phenotypic traits with CFC. Including this case, at present, germline mutations in *MAP2K1* and *BRAF* genes are associated with CFC and LS. CALM and multiple nevi or lentigines are rare or absent in CFC patients with Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutations ([@b25-mmr-14-05-4023]), further demonstrating the complicated genetic heterogeneity and prominent overlapping feature of RASopathies.

CALM precede or are associated with lentigines in\~10% of NS cases ([@b26-mmr-14-05-4023]), and in up to 75% of LS cases ([@b27-mmr-14-05-4023]), furthermore, in LS cases, the number of CALM can fulfills NIH criteria for diagnosis with NF1 ([@b28-mmr-14-05-4023]). Lentigines usually appear during childhood as black-brown macules, predominantly on the face, neck and upper part of the trunk, and gradually increase in number and darken in color with age. Although LS patients have unclear disposition to malignancies, certain studies have reported an association with hematologic malignancies ([@b29-mmr-14-05-4023]) and medulloblastoma ([@b30-mmr-14-05-4023]), which should be noted.

### NS-CFC-CS spectrum

NS shares numerous congenital anomalies with LS, excluding multiple lentigines. CFC and CS also have various clinical similarities and few differences compared with NS ([@b25-mmr-14-05-4023]). Previously, clinical discrimination between these three syndromes was predominantly based on respective characteristic features, including hyperkeratotic skin, ichthyosis and keratosis pilaris in CFC patients; and soft and loose skin, deep palmar/plantar creases, nasal papillomas and an increased risk of developing malignancies in those with CS ([@b31-mmr-14-05-4023],[@b32-mmr-14-05-4023]). However, as the reported cases of RASopathies increase, these distinct features have also become highly overlapped.

Previous studies have demonstrated that one or two CALM are observed in 9--31% of individuals in NS-CFC-CS spectrum disorders, this is markedly higher than the overall prevalence of 2.5% in neonates ([@b33-mmr-14-05-4023]), while multiple CALM and intertriginous freckling were rare or absent ([@b25-mmr-14-05-4023],[@b26-mmr-14-05-4023],[@b34-mmr-14-05-4023]). In combination with the less common dysmorphic craniofacial features in NF1, the discrimination between these conditions and NF1 is relatively easier.

*KRAS* mutations associated with the NS-CFC-CS spectrum predominantly confer mild gain-of-function effect ([@b35-mmr-14-05-4023]). The present review suggests that *KRAS* mutations associated with the NS-CFC-CS spectrum belong to an identical entity relatively close to NS (see [Table I](#tI-mmr-14-05-4023){ref-type="table"}, which provides a proper hypothesis for a new classification of these RASopathies and corresponding causal genes) as: i) CFC, NS and CS exhibit numerous clinical similarities and few differences ([@b25-mmr-14-05-4023],[@b36-mmr-14-05-4023],[@b37-mmr-14-05-4023]); ii) *KRAS* mutations have been reported in \<2% of the NS and CFC cases ([@b37-mmr-14-05-4023]), as well as in only a handful of CS patients ([@b35-mmr-14-05-4023],[@b38-mmr-14-05-4023]), and all three of the independent conditions demonstrated their major pathogenic form, *PTPN11*, *BRAF* and *HRAS*, respectively (presented in [Table I](#tI-mmr-14-05-4023){ref-type="table"}); iii) mutations Asp153Val, Thr58Ile and other missense mutations in the same amino acid residue in *KRAS* were reported to result in NS and CFC ([@b25-mmr-14-05-4023],[@b39-mmr-14-05-4023],[@b40-mmr-14-05-4023]); iv) less prominent ectodermal phenotypes were observed in CFC and CS with *KRAS* mutations than those with *BRAF* mutations ([@b25-mmr-14-05-4023],[@b34-mmr-14-05-4023],[@b39-mmr-14-05-4023],[@b41-mmr-14-05-4023]); v) multiple nevi or lentigines were rare or absent in CFC patients with *KRAS* mutations compared with those with mutations in *MAP2K1* and *BRAF* ([@b25-mmr-14-05-4023]).

In the majority of instances, *BRAF* mutations resulting in NS have not been observed in CFC, suggesting the associated phenotypes may be allele specific ([@b42-mmr-14-05-4023]), however, a number of *BRAF* mutations, including Ala246Pro and Gln257Arg, have been demonstrated in the two conditions ([@b25-mmr-14-05-4023]).

Previous studies have also demonstrated the evolution of the clinical phenotype in a CFC patient, and the marked resemblance between CFC and NS, consistent with the suggestion that NS and CFC are variable manifestations of the same entity ([@b36-mmr-14-05-4023],[@b43-mmr-14-05-4023]).

Taking updated molecular findings, reviews of complex genetic heterogeneity and the highly overlapping features of these disorders into consideration, the present review hypothesizes these three disorders may be not distinct and separate conditions, but a continuous spectrum consisting of a certain gene or group of gene-related subtypes with certain degrees of phenotypic variability, particularly *KRAS*-associated NS-CFC-CS spectrum (as presented in [Table I](#tI-mmr-14-05-4023){ref-type="table"}), or multiple alternative underlying mechanisms are involved in the functional dysregulation of the Ras/MAPK signaling pathway.

### Allelic syndromes of NF1: Neurofibromatosis-Noonan syndrome and Watson syndrome

The disorder designated neurofibromatosis-Noonan syndrome (NFNS; OMIM 601321) is a variant of NF1 rather than NS, predominantly due to mutations in the *NF1* gene ([@b44-mmr-14-05-4023]). It may fulfill the criteria for NF1 with CALM and skin-fold freckling, but also has overlapping features with NS, including 'Noonan' face, short stature, congenital heart defects and a predisposition to malignancy.

Watson syndrome (WS; OMIM 193520) is characterized by pulmonic stenosis, CALM and intellectual impairment ([@b45-mmr-14-05-4023]), furthermore, Lisch nodules are observed in the majority of affected subjects, and neurofibromas in \~1/3 ([@b46-mmr-14-05-4023]). An 80-kb deletion and an in-frame tandem duplication of 42 bases at the *NF1* locus have been reported in patients with WS ([@b47-mmr-14-05-4023],[@b48-mmr-14-05-4023]). These findings broaden the noteworthy *NF1*-associated phenotype spectrum and are consistent with NFNS and WS as allelic disorders or subtypes of NF1. An alternative explanation is that they are the result of an additive effect of mutations in *NF1* and other relevant genes, including *PTPN11* or unknown modifying loci ([@b49-mmr-14-05-4023],[@b50-mmr-14-05-4023]).

3.. KITLG/KIT signaling pathway-associated genetic disorders with CALM
======================================================================

### Piebaldism

Piebaldism is a rare autosomal dominant disorder caused by *KIT* mutations. Characteristic features are depigmented patches of skin and hair (as presented in [Fig. 1](#f1-mmr-14-05-4023){ref-type="fig"}). Of the three reported piebaldism cases with multiple CALM and intertriginous freckling, all the mutations were located in the tyrosine kinase (TK) domain (Gly610Asp, Gliu640Asp and Arg791Gly) ([@b51-mmr-14-05-4023]--[@b53-mmr-14-05-4023]). It has been demonstrated that inadequate phosphorylation of the KIT-binding domain in SPRED1 due to a defective KIT TK would result in loss of inhibition of the Ras⁄MAPK signaling pathway, leading to a phenotype similar to NFLS ([@b53-mmr-14-05-4023]), while gain-of function mutations in KITLG have been reported to result in FPHH ([@b54-mmr-14-05-4023]), indicating KIT and KITLG are important modulators of skin pigmentation.

Phenotypic severity depends on the type and site of the mutation ([@b55-mmr-14-05-4023],[@b56-mmr-14-05-4023]). Mutations in the TK region (TK1, 582--684 and TK2, 762--973) exert a dominant-negative effect, usually resulting in a severe phenotype, whereas mild cases are frequently due to mutations in the extracellular region.

Patients with piebaldism may develop CALM (as presented in [Fig. 1](#f1-mmr-14-05-4023){ref-type="fig"}), NF1 may be associated with piebaldism, and these two distinct conditions may co-exist in one patient ([@b57-mmr-14-05-4023],[@b58-mmr-14-05-4023]), which highlights the necessity of molecular diagnosis.

### FPHH and FPH

FPHH is notable for progressive, diffuse, partly blotchy hyperpigmented lesions intermingled with scattered hypopigmented spots, lentigines and CALM (as presented in [Fig. 2](#f2-mmr-14-05-4023){ref-type="fig"}) ([@b6-mmr-14-05-4023]). It is the result of a mutation in *KITLG*, encoding KITLG involved in the Ras⁄MAPK signaling pathway ([@b54-mmr-14-05-4023]). Clinical signs are somewhat different from its allelic disorder FPH ([@b59-mmr-14-05-4023]), in which no hypopigmentation is present. Notably, the mutation p.Asn36Ser results in FPH and FPHH, with the FPH patient image in a previous study by Wang *et al* ([@b59-mmr-14-05-4023]) also demonstrating small suspicious hypopigmented lesions ([@b54-mmr-14-05-4023]). This suggests these two disorders may resemble another pigmentary genetic disorder termed Dowling-Degos disease (DDD; OMIM 179850, 615327 and 615696) ([@b60-mmr-14-05-4023]--[@b63-mmr-14-05-4023]), which may also be the same condition with a degree of phenotypic variability, for example, in the distribution of hyperpigmented and hypopigmented lesions.

4.. Conclusion
==============

The RASopathies have complex genetic heterogeneity and marked overlapping features, however, a relatively correct diagnosis is essential for genetic counseling regarding prognosis (as the diagnosis of milder phenotypes, including NFLS or mosaic NF1, may relieve the psychological burden on serious age-dependent complications); monitoring of potential risks, including cancer and cardiac events; and prevention using prenatal diagnosis.

Thus, the current review proposes a screening strategy in which: i) *NF1* testing has a priority for patients that only exhibit CALM or fulfill the NIH diagnostic criteria for NF1; ii) *SPRED1* and *NF1* should be tested in those with skin-fold freckling and a family history; iii) in *NF1*-negative pediatric patients with CALM and a dispersed pattern of facial and cervical freckles, *PTPN11* should be first considered for molecular analysis, as it accounts for the majority of LS and NS cases; iv) genetic testing of *KITLG* and *KIT* is used and relatively effective in those with diffuse hyperpigmented lesions intermingled with scattered depigmentation, depigmented patches of skin and hair, respectively (as presented in [Fig. 3](#f3-mmr-14-05-4023){ref-type="fig"}).

As for other RASopathies, *BRAF* and *HRAS* analysis is suitable for relatively typical CFC and CS presentations, respectively. However, when considering the highly overlapping phenotypes and involvement of numerous genes, a custom-designed screening kit including all the candidate genes for the various RASopathies is a thorough alternative choice.

Furthermore, few patients with CALM fall outside the above mentioned disorders and their condition may be the result of mutations in other undetected genes associated with the Ras/MAPK signaling pathway, for instance, recently identified causal genes Cbl proto-oncogene E3 ubiquitin protein ligase and Ras-like without CAAX 1 ([@b64-mmr-14-05-4023],[@b65-mmr-14-05-4023]). Considering the detection limit of general sequencing methods, especially for those atypical or unreported phenotypes, next generation sequencing (such as whole exome sequencing and whole genome sequencing) still serves as a cost-effective approach for molecular diagnosis of the above disorders with CALS, as well as other possible genetic diseases, including neurofibromatosis type 2 (OMIM 101000) with vestibular schwannomas; McCune-Albright syndrome (OMIM 174800) with segmental CALM, polyostotic fibrous dysplasia and precocious puberty; constitutional mismatch repair deficiency syndrome (OMIM 276300) with childhood cancer predisposition ([@b66-mmr-14-05-4023]); and various mosaic conditions associated with CALM (as presented in [Fig. 3](#f3-mmr-14-05-4023){ref-type="fig"}).
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![Screening strategies for inherited disorders with CALM that clinically resemble NF1, particularly those involved in KITLG/KIT and Ras/mitogen-activated protein kinase signaling pathways. CALM, café-au-lait macules; NF1, neurofibromatosis type 1; KIT, KIT proto-oncogene receptor tyrosine kinase; KITLG, KIT ligand; SPRED1, sprouty related, EVH1 domain containing 1; PTPN11, protein tyrosine phosphatase, non-receptor type 11; NF2, neurofibromatosis type 2; MAS. McCune-Albright syndrome; CMMRDS, constitutional mismatch repair deficiency; NGS, next generation sequencing.](MMR-14-05-4023-g02){#f3-mmr-14-05-4023}

###### 

'NF1-like' genetic disorders with CALM involved in KITLG/c-Kit and Ras/MAPK signaling pathways.

  Genetic disorder   Known causal genes (proportion)                                                                               Disease identity                       Gene identity                          Characteristic features
  ------------------ ------------------------------------------------------------------------------------------------------------- -------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NS                 PTPN11 (50%) SOS1 (10--15%) RAF1 (5%) RIT1 (5%) KRAS (\<2%) BRAF (rare) NRAS (rare) SHOC2 (rare) CBL (rare)   NS                                     PTPN11 SOS1 RAF1 RIT1 NRAS SHOC2 CBL   CALM (10%). Dysmorphic craniofacial features, cardiac defect (pulmonary valve stenosis, hypertrophic cardiomyopathy), musculoskeletal abnormalities, mental retardation, cryptorchidism, hematologic malignancies
                                                                                                                                   *KRAS*-associated NS-CFC-CS spectrum   KRAS                                   Less prominent ectodermal phenotypes; multiple nevi or lentigines were rare or absent
  CFC                BRAF (50--70%) MAP2K1/2 (25%) KRAS (\<2%)                                                                     CFC                                    BRAF MAP2K1/2                          CALM (9--31%). Similar to NS. Ectodermal abnormalities such as multiple nevi, keratosis pilaris, ulerythema ophryogenes and brittle, sparse, curly hair. Potential cancer risk
  CS                 HRAS (\>90%) BRAF (rare) KRAS (rare)                                                                          CS                                     HRAS                                   CALM (rare). Similar to NS. Ectodermal abnormalities like soft skin, deep palmar/plantar creases, papillomas and curly hair. Severe failure to thrive. Significant cancer risk (17%)
  LS                 PTPN11 (85%) RAF1 (rare) BRAF (rare) MAP2K1 (1 case)                                                                                                                                        CALM (70--80%). Similar to NS, but with multiple lentigines mostly on face, neck and upper part of the trunk. Unclear cancer risk
  NFLS               SPRED1                                                                                                                                                                                      Multiple CALM (nearly 100%), intertriginous freckling. Potential risk of pediatric AML
  Piebaldism         KIT                                                                                                                                                                                         Depigmented patches of skin and hair
  FPH and FPHH       KITLG                                                                                                         FPHH                                   KITLG                                  Diffuse, partly blotchy hyperpigmented lesions intermingled with scattered hypopigmentations, lentigines and CALM

NF1, neurofibromatosis type 1; CALM, café-au-lait macules; KITLG, KIT ligand; c-Kit, KIT proto-oncogene receptor tyrosine kinase; MAPK, mitogen-activated protein kinase; NS, Noonan syndrome; CFC, cardiofaciocutaneous syndrome; CS, Costello syndrome; LS, LEOPARD syndrome; NFLS, NF1-like syndrome, Legius syndrome; FPH, familial progressive hyperpigmentation; FPHH, familial progressive hyper- and hypopigmentation; HRAS, Harvey rat sarcoma viral oncogene homolog; KRAS, Kirsten rat sarcoma viral oncogene homolog; PTPN11, protein tyrosine phosphatase, non-receptor type 11; SOS1, son of severnless homolog 1; RAF1, Raf-1 proto-oncogene serine/threonine protein kinase; RIT1, Ras-like without CAAX 1; BRAF, B-Raf proto-oncogene, serine/threonine kinase; NRAS, neuroblastoma RAS viral oncogene homolog; SHOC2, SHOC2 leucine-rich repeat scaffold protein; CBL, Cbl proto-oncogene, E3 ubiquitin protein ligase; MAP2K, MAPK kinase; SPRED1, sprouty related, EVH1 domain containing 1.
